First Shipment of Revolutionary UltraShear Nanoemulsion Skin Care Selling on QVC, Over $1 Million Revenue: PBIO

$PBIO Corporate

$PBIO Corporate


PBIO Products

PBIO & Dr. Denese..


$75,000 Pilot Lot Payment Received for Phase I of Safer Medical of Montana Agreement; Phases II/III Commercial Scale-Up. 1st Half 2023 Revenues Over $1 Million

Pressure BioSciences, Inc. (OTCMKTS:PBIO)

SOUTH EASTON, EASTON, MASSACHUSETTS, UNITED STATES, December 13, 2022 / -- First Shipment of Revolutionary UltraShear Nanoemulsion Skin Care Selling on QVC, Over $1 Million Revenue Projection: Pressure BioSciences, Inc. (Stock Symbol: PBIO)

$75,000 Pilot Lot Payment Received for Phase I of Safer Medical of Montana Agreement; Phases II/III Commercial Scale-Up. 1st Half 2023 Revenues Over $1 Million

 Focus on the Development & Worldwide Sale of Innovative, Broadly Enabling, Pressure-Based Solutions for Life Sciences and Other Applications.

 Cooperative Work with QVC Skincare Leader Dr. Denese SkinScience Yields Unprecedented Effectiveness in Skin Tightening & Wrinkle Reduction.

 First Commercial Production of UltraShear Nanoemulsion Product Shipped, Booked, and Paid. Commercial Scale-Up Expected to Yield 1st Half 2023 Revenues Over $1 Million.

 Patented UltraShear™ to Process Components of Successful Anti-Aging Products Sold by Dr. Denese to Extremely Fine and Consistent Nanoemulsions.

 Dr. Denese SkinScience Sold Over $500 Million Science-Driven Skincare Products Through QVC Alone Over the Past 20 Years.

 Company Q3 Operational Results Show Marked Improvements in Key Areas.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for worldwide life sciences and other industries. PBIO products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, and biomolecule extraction).

The PBIO primary company focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of PBIO pressure-based technologies in the following areas: (1) the use of recently acquired, patented technology from BaroFold, Inc. (the "BaroFold" technology) to allow entry into the bio-pharma contract services sector, and (2) the use of recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 First Commercial Production of Revolutionary UltraShear Nanoemulsion Product Shipped, Booked and Paid

On December 13th PBIO confirmed the shipment of their first-ever commercial production lot of a revolutionary nanoemulsion product created and enabled by the PBIO innovative Ultra Shear Technology™ (UST™ or UltraShear™) nano emulsification platform. The shipped product is a breakthrough CBD oral spray designed by PBIO for fast effect and high potency for Safer Medical of Montana ("SMM"), with whom PBIO signed a multi-year development and manufacturing agreement announced on May 4, 2022. SMM pre-paid the entire $75,000 purchase price of the Phase I production lot.

The Agreement covers three phases of development and commercialization of a custom-formulated oral spray of hemp-derived nano-emulsified CBD designed for extremely rapid absorption and effectiveness, and for efficient high-potency delivery of CBD active material in each dose. All ingredients used in the manufacture of this UltraShear prepared nanoemulsion product are sourced from naturally occurring, plant-based origins. Phases II and III of the PBI-SMM Agreement are focused on scaling up UltraShear nanoemulsion production by a factor of 10x in each stage, with total PBIO revenues captured under this Agreement expected to top $1M in Q1/Q2 of 2023.

 Partnership with QVC Skincare Leader Dr. Denese SkinScience Yields Unprecedented Effectiveness in Skin Tightening and Wrinkle Reduction

On December 7th PBIO confirmed that initial results from their first stage of product development under the company’s August 2022 collaboration agreement with renowned skincare expert Dr. Adrienne Denesehave greatly exceeded all expectations.

The first stage of the Agreement calls for PBIO to apply their patented Ultra Shear Technology™ (UST™ or UltraShear™) to process oil-based active components used in many highly successful anti-aging products currently sold by Dr. Denese into extremely fine and consistent nanoemulsions, with the expectation that resulting improvements in topical bioavailability will drive these already market-leading products to even higher levels of performance. The companies chose two important, commonly used active ingredients for their initial collaborative development of valuable new skincare product lines, both of which would leverage PBIO proprietary UltraShear nano emulsification process: (i) retinol (and its derivative retinoate) and (ii) lipid-soluble Vitamin C. These compounds are important ingredients in multiple Dr. Denese SkinScience anti-aging products and were discussed recently in the FORCE Family Office sponsored Development of a New Generation of Skincare Products webinar (PBIO/Dr. Denese FORCE Webinar 101322).

Retinol (and its derivative retinoate) is a form of Vitamin A used in multiple skincare products, such as lotions, creams, and serums. It has excellent antioxidant properties and is regarded as the number one anti-aging, wrinkle-fighting, and skin-tightening ingredient in the marketplace. It is also the number one choice in acne treatment. It delivers proven anti-aging effects via encouraging the production of collagen. Retinol is known to be a strong irritant of the skin, but there are Vitamin A derivatives, such as retinoate, which have been found to be far more effective yet less of an irritant than retinol.
Dr. Adrienne Denese, M.D., Ph.D. is a globally-acknowledged skincare visionary and anti-aging pioneer. As Founder and President of Dr. Denese SkinScience, she has sold over $500M of her science-driven skincare products through QVC alone over the past 20 years. Dr. Denese thoroughly tested the newly developed UltraShear-nano emulsified retinoate and has excitedly reported: "I have never encountered such profound skin tightening and wrinkle-reducing effects as I have experienced with PBI's UltraShear-processed retinoate serum. I am known for using very high levels of skincare active ingredients in my product formulations, in order to make my skincare products, especially effective compared to everyone else in the industry. However, even compared to my already effective serums, the UltraShear-processed retinoate performance far exceeded anything that I have ever seen until today. Simply put, it is my opinion that PBI's UltraShear platform is an industry-redefining innovation."

 PBIO Reports Q3 2022 Financial Results

On November 22nd PBIO reported financial results for the third quarter that ended September 30, 2022, provided a business update, and offered guidance for a strong finish to 2022 and a growth drive to expected profitability in 2023.

Financial Results: Q3 2022 vs. Q3 2021

Total revenue for Q3 2022 was $144,000 compared to $518,000 for Q3 2021, a decrease of 72%.

Instrument sales for Q3 2022 were $134,000 compared to $419,000 for Q3 2021, a decrease of 66%.

PBIO Agrochem subsidiary sales in Q3 2022 were $10,000 compared to $17,000 for Q3 2021, a decrease of 41%.

Operating loss for Q3 2022 was $1,363,000 compared to $1,243,000 for Q3 2021, an increase of 10%.

Basic and diluted net loss per share was $(0.44) for Q3 2022, improved from $(0.82) for Q3 2021.

Recent Operational and Technical Highlights:

October 26: PBIO and skincare pioneer and leading innovator Dr. Adrienne Denese, M.D., Ph.D. to introduce revolutionary UST nanoemulsion-based hair loss prevention and hair regrowth product line in 2023.

September 28: Imminent Commercial Launch of Revolutionary UST Processing Method to be Focus of PBI's Presentation at Emerging Growth Conference 40.

September 27: Unique Advantages and Commercial Process Scalability of PBIO Revolutionary UST Platform Illuminated at the Conference of Food Engineering 2022.

September 13: PBIO to Expand on Pivotal Change in Business Strategy with Presentation at HC Wainwright Annual Global Investment Conference.

August 24: PBIO secures pivotal cosmeceuticals partnership for UST platform with Dr. Denese SkinScience, a 20-year industry leader with over $500 million in QVC sales.

August 18: The third contract was announced for hemp-derived CBD products, estimating $2 million in 2023 revenue.

August 11: PBIO receives approval to manufacture hemp-derived CBD products in Mass, including novel CBD nano emulsions processed by the Company's revolutionary Ultra Shear Technology (UST) platform.

DISCLAIMER: This article is purely for informational purposes and is not a recommendation in any way for buying or selling stocks

Richard T. Schumacher, President & CEO
Pressure BioSciences, Inc.
+1 508-230-1828
email us here
Visit us on social media: